Compass, Inc. (COMP) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 11.11%. A quarter ago, it was expected that this company would post a loss of $0.03 per share when it actually produced break-even earnings, delivering a surprise of 100%.Over the last four quarters, the company has surpasse ...

Revenue in Q4 Grew 25.9% YoY and Organic Revenue Grew 20.9% YoYQuarterly Market Share Grew 65bps YoY to 5.06% and Organic Share Was Up 48bps$122 Million in Full-Year Operating Cash Flow; $150 Million Prior to NAR-related SettlementNEW YORK, Feb. 18, 2025 /PRNewswire/ -- Compass, Inc. (NYSE: COMP) ("Compass" or "the Company"), a leading tech-enabled real estate services company that includes the largest residential real estate brokerage in the United States by sales volume1, announced its financial results f ...

Compass (COMP) is scheduled to report its fourth-quarter 2024 results on Feb. 18.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.For the fourth quarter of 2024, COMP expects total revenues in the range of $1.225-$1.325 billion.The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $1.28 billion, indicating a 16.65% increase from the figure reported in the year-ago quarter.The consensus mark is pegged at a loss of 10 cents per share, which remained unchanged over the pas ...

Compass Minerals International, Inc. CMP reported weaker-than-expected first-quarter adjusted EPS results and cut its FY25 salt segment revenue guidance, after the closing bell on Monday.Compass Minerals Intl reported quarterly losses of 55 cents per share which missed the analyst consensus estimate of 15 cents per share. The company reported quarterly sales of $307.20 million which beat the analyst consensus estimate of $294.00 million.“This quarter we began to see results from our back-to-basics strategy ...

The company's flagship salt segment faced both weather-related challenges and the near-term impacts of its decision to slim its inventories.Compass Minerals International (CMP -4.46%), a leader in salt and specialty plant nutrition production, delivered a mixed report for its fiscal 2025 first quarter on Feb. 10. The company's non-GAAP loss of $0.55 per share contrasted with the earnings per share (EPS) of $0.13 anticipated by analysts. However, on the revenue front, Compass Minerals posted $307.2 million, ...

NEW YORK, Feb. 5, 2025 /PRNewswire/ -- Compass, Inc. (NYSE: COMP), the largest residential real estate brokerage in the United States by sales volume1, today announced its fourth quarter and full-year 2024 financial results will be released after market close on Tuesday, February 18, 2025. The company will host a conference call and webcast to discuss its results that afternoon at 5:00 p.m. ET / 2:00 p.m. PT.Call details are as follows: The conference call will be accessible online via the Compass Investor ...

Compass Provides Agents with a Platform to Guide Buyers and Sellers Through Every Step of Their Homeownership JourneyNEW YORK, Feb. 3, 2025 /PRNewswire/ -- Compass (NYSE: COMP), the largest residential real estate brokerage in the United States by sales volume1, announces the launch of Compass One, the client-facing version of its end-to-end technology platform for real estate agents. Compass One is the only platform designed to connect you and your agent through every phase of your real estate journey and ...

Core Viewpoint - Shares of Compass Therapeutics (CMPX) have increased by 108.3% in one month due to positive updates on pipeline development and cash position, reflecting strong investor expectations for the company's potential in oncology-focused therapeutics [1] Group 1: Lead Pipeline Program - CMPX's lead candidate, tovecimig (CTX-009), is in a phase II/III study with paclitaxel for advanced biliary tract cancer (BTC) patients who have had one prior chemotherapy [2] - The study aims to evaluate the safety and efficacy of the tovecimig/paclitaxel combination compared to paclitaxel alone in second-line treatment settings [2] - Top-line data is expected to be reported in the U.S. by the end of Q1 2025, with the combination having received FDA's Fast Track designation for BTC treatment [4] Group 2: Other Pipeline Programs - Compass Therapeutics is planning a phase II study of CTX-471 (CD137 agonist) for tumors expressing NCAM in mid-2025 [8] - An early-stage dose-escalation study of CTX-8371 (PD-1 x PD-L1 bispecific antibody) has completed patient enrollment in its third dosing cohort [8] - The novel PD-1 x VEGF-A bispecific antibody, CTX-10726, is set for investigational new drug application submission by the end of the year, with initial clinical data expected in 2026 [9] Group 3: Financial Position - As of December 31, 2024, Compass Therapeutics estimates a cash balance of $127 million, which is projected to support operations into Q1 2027 [9] Group 4: Stock Performance - CMPX shares have surged 77.6% over the past three months, contrasting with a 7.1% decline in the industry [3]

Core Viewpoint - Compass, Inc. has been upgraded to a Zacks Rank 1 (Strong Buy), indicating a positive outlook on its earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Performance - The Zacks rating system is based on changes in earnings estimates, which are closely correlated with stock price movements [4][6]. - An increase in earnings estimates typically leads to higher fair value calculations by institutional investors, resulting in buying or selling pressure that affects stock prices [4]. Recent Developments for Compass - Compass is expected to earn -$0.33 per share for the fiscal year ending December 2024, reflecting a year-over-year change of 52.2% [8]. - Over the past three months, the Zacks Consensus Estimate for Compass has increased by 251%, indicating a strong upward trend in earnings estimates [8]. Zacks Rank System - The Zacks Rank system classifies stocks into five groups based on earnings estimates, with Zacks Rank 1 stocks historically generating an average annual return of +25% since 1988 [7]. - The upgrade of Compass to Zacks Rank 1 places it in the top 5% of Zacks-covered stocks, suggesting potential for market-beating returns in the near term [10].

Company Overview - Compass, Inc. (COMP) shares increased by 19.4% to close at $6.66, following a period of 16.7% loss over the past four weeks, indicating a significant recovery in stock performance [1] - The company is experiencing strong transaction growth, record agent retention, and enhanced operational efficiencies, which have led to an upward revision of its revenue forecasts for Q4 2024 and full-year 2024 [2] Financial Performance - The revised revenue forecast for Q4 2024 is now between $1.36 billion and $1.39 billion, up from the previous estimate of $1.225 billion to $1.325 billion [2] - The full-year 2024 revenue forecast has also been increased to between $5.61 billion and $5.64 billion, compared to the earlier forecast of $5.47 billion to $5.57 billion [2] - The upcoming quarterly report is expected to show a loss of $0.10 per share, which represents a year-over-year change of +41.2%, with revenues anticipated to be $1.28 billion, reflecting a 16.7% increase from the previous year [3] Market Sentiment - The consensus EPS estimate for Compass has remained unchanged over the last 30 days, suggesting stability in earnings expectations [4] - The stock currently holds a Zacks Rank of 1 (Strong Buy), indicating positive market sentiment towards its future performance [4] - In comparison, DigitalOcean Holdings, Inc. (DOCN), another company in the same industry, has a Zacks Rank of 3 (Hold) and has seen a decline of 11.1% over the past month [4][5]